P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs)
P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) is a paper indexed in ScholarIQ from OpenAlex.
How many citations does P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) have?
P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) has 0 citations in the OpenAlex counts ScholarIQ stores.
When was P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) published?
P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) has 2021 year in the ScholarIQ index.
What is the open-access status of P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs)?
P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) has bronze oa status in the ScholarIQ index.
What is the DOI of P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs)?
The DOI for P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) is on the source record.
What is the OpenAlex record for P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs)?
The OpenAlex for P02.02 Pulmonary Rebiopsy is ‘Here to Stay’ in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs) is on the source record.